Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGARI: Amantadine Triple Therapy in HCV Non-Responders
NCT00221624Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C (HCV) comparing Amantadine Triple Therapy with Placebo Control (2 arms). Primary endpoint: Sustained Virological Response. Started Nov 2001; status: completed.
02
Drugs
amantadine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00221624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221624.